F

    FibroBiologics, Inc. Common Stock (FBLG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.72
    +0.28 (+19.44%)

    Market Cap: $9.59M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(7/9)
    Avg Surprise
    +33.07%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.63 - $-0.63
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.77-22.2%
    60d ago$-0.94-49.2%
    30d ago$-0.94-49.2%
    7d ago$-0.94-49.2%
    Current$-0.63
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.63---
    Jun 26
    		$-0.66$-0.93+29.03%Beat-450.0%
    Mar 26
    		$-1.33$-1.35+1.84%Beat+52.5%
    Dec 25
    		$-0.60N/A+70.00%Beat-566.7%
    Sep 25
    		$-2.60$-2.30-13.04%Miss-1200.0%
    Jun 25
    		$-0.12$-0.12+0.00%Beat-120.0%
    Mar 25
    		$-2.80$-2.50-12.00%Miss-937.0%
    Dec 24
    		$-0.09$-0.09+0.00%Beat-
    Sep 24
    		$-0.20N/A+88.44%Beat-
    Jun 24
    		$0.60N/A+133.33%Beat-
    Mar 24
    		$-0.27N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.33EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-660.00%ROIC-306.57%
    Financial Health
    Debt/Equity0.03xInterest CoverageN/A
    Current Ratio2.64xQuick Ratio2.64x
    Trading Statistics
    Beta1.22Avg Volume273.50K
    52-Week High$12.5652-Week Low$0.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.39
    SMA 20$1.20
    SMA 50$0.95
    SMA 200$3.36
    EMA 10$1.40
    EMA 20$1.24
    EMA 50$1.15
    EMA 200$3.89

    MACD

    Line: 0.18Signal: 0.13Hist: 0.05

    ADX

    ADX: 46.1+DI: 36.5-DI: 5.8

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$1.40

    Bollinger Bands

    Upper Band$1.67
    Lower Band$0.72
    %B Position7916%(Upper)
    Band Width1.05

    RSI (14-Day)

    Overbought
    77.4

    Momentum Oscillators

    Stoch %K89.4
    Stoch %D87.9
    Williams %R-8.6
    ROC (10d)68.6%
    Momentum0.70
    CCI (20d)151.8
    MFI (14d)79.4

    Volatility Measures

    ATR (14d)$0.15(8.6%)
    StdDev (20d)0.24
    Hist Vol117.0%(High)

    Volume Flow

    VWAP$1.64
    OBV-41.3M
    AD Line89.8B
    CMF (20d)0.098

    Volume Metrics

    Avg Vol (20d)274.0K
    Vol Ratio1.7x(High)
    VWMA (20d)$1.24

    Pivot Points

    R3$1.65
    R2$1.59
    R1$1.52
    Pivot Point$1.46
    S1$1.39
    S2$1.33
    S3$1.26

    Advanced Oscillators

    TSI42.08
    Ultimate Osc56.0
    KST672.60

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$554,000$0$0$0$0$0
    Cost of RevenueN/AN/A$234,000$231,000$206,000N/A$153,000N/A$140,000$137,000$130,000$112,000
    Gross ProfitN/AN/A$-234,000$-231,000$-206,000N/A$277,000N/A$-140,000$-137,000$-130,000$-112,000
    Operating Expenses$4.03M$5.07M$2.36M$5.04M$4.49M$4.53M$3.71M$3.35M$3.22M$3.45M$2.48M$2.05M
    R&D$1.66M$2.95M$797,000$2.79M$2.04M$1.78M$1.36M$1.21M$975,000$960,000$773,000$571,000
    SG&A$2.38M$2.12M$1.79M$2.25M$2.45M$2.75M$2.36M$2.14M$2.25M$2.49M$1.71M$1.48M
    Operating Income$-4,033,000$-5,068,000$-2,590,000$-5,038,000$-4,490,000$-4,531,000$-3,712,000$-3,352,000$-3,224,000$-3,450,000$-2,480,000$-2,052,000
    Interest Income$15,000$20,000$25,000$73,000$50,000$99,000$63,000$79,000$70,000$39,000$0$0
    Interest Expense$7,000$4,000$204,000$0$0$0$6,000$5,000$5,000$4,000$1,000$0
    Income Before Tax$-4,117,000$-5,000,000$-3,244,000$-5,778,000$-4,658,000$-4,966,000$-3,099,000$-500,000$898,000$-8,460,000$-9,717,000$-2,193,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$1
    Net Income$-4,117,000$-5,000,000$-3,244,000$-5,778,000$-4,658,000$-4,966,000$-3,099,000$-500,000$898,000$-8,460,000$-9,717,000$-2,193,000
    EBITDA$-4,033,000$-4,759,000$-2,806,000$-5,547,000$-4,452,000$-4,805,000$-2,940,000$-352,000$1.04M$-8,319,000$-9,586,000$-2,081,000
    EBITN/A$-4,996,000$-3,040,000$-5,778,000$-4,658,000$-4,966,000$-3,093,000$-495,000$903,000$-8,456,000$-9,716,000$-2,193,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBLG

    News

    FibroBiologics Adds Leigh Steinberg to Board for Growth

    FibroBiologics has appointed Leigh Steinberg, a renowned sports agent with five decades of dealmaking experience, to its board of directors. Steinberg's extensive network and advocacy in human longevity and brain health are expected to strengthen the company's strategic position as it develops fibroblast-based therapies. While an analyst has issued a Buy rating with a $6.00 price target, TipRanks' AI Analyst, Spark, rates FBLG as Neutral due to weak financial performance and delisting risk.

    The Globe and Mail•8/25/26•
    Neutral

    FibroBiologics Adds Sports Agent Leigh Steinberg to Board of Directors

    FibroBiologics has appointed renowned sports agent Leigh Steinberg to its Board of Directors, bringing his extensive experience in negotiation, sports, and healthcare advocacy to the clinical-stage biotechnology company. Steinberg, known for representing numerous professional athletes and his long-standing interest in brain health and longevity, will help FibroBiologics as it advances its fibroblast-based therapeutic pipeline for chronic diseases and human longevity. This appointment aims to leverage Steinberg's unique background to support the company's strategic growth, partnerships, and commercialization efforts.

    citybiz•8/24/26•
    Somewhat-Bullish

    FibroBiologics appoints Leigh Steinberg to board

    FibroBiologics, Inc. (NASDAQ:FBLG), a clinical-stage biotechnology company, has appointed Leigh Steinberg, CEO of Steinberg Sports & Entertainment, to its Board of Directors. Steinberg brings over 50 years of experience representing professional athletes and a history of advocating for health, particularly in traumatic brain injury research. His appointment is expected to leverage his network and expertise as FibroBiologics develops therapeutics for chronic diseases using fibroblast cell therapy.

    Investing.com•8/24/26•
    Somewhat-Bullish

    Fibro appoints Leigh Steinberg as Class II director

    Fibro has announced the appointment of Leigh Steinberg as a Class II director to its Board, effective August 20, 2026. Steinberg will receive compensation consistent with other non-employee directors and has executed a standard indemnification agreement. This information is based on an SEC 8-K filing from FibroBiologics, Inc. (FBLG).

    TradingView•8/24/26•
    Somewhat-Bullish

    Leigh Steinberg, agent behind $4B in deals, joins FibroBiologics (FBLG) board

    FibroBiologics, Inc. (FBLG) has appointed legendary sports agent Leigh Steinberg as a Class II director to its board, effective August 20, 2026. Steinberg, known for negotiating over $4 billion in contracts and his advocacy for human longevity and brain health, will serve until the 2028 annual meeting of stockholders. This appointment is expected to leverage his extensive experience and network as FibroBiologics advances its fibroblast-based therapeutics, including its human longevity program.

    Stock Titan•8/24/26•
    Somewhat-Bullish

    Frequently Asked Questions About FBLG

    Does FBLG pay dividends?
    FibroBiologics, Inc. Common Stock (FBLG) does not currently pay a regular dividend.
    What is FBLG's market cap?
    FibroBiologics, Inc. Common Stock (FBLG) has a market capitalization of $9.59M with a current stock price of $1.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In